{
  "claim_id": "claim_000",
  "claim": "Flublok Quadrivalent is approved for adults 18 years and older.",
  "document": {
    "pdf_name": "FlublokPI",
    "source_pdf": "data/clinical_files/FlublokPI.pdf",
    "total_pages": 5,
    "total_blocks": 94,
    "total_characters": 25545
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 3,
    "error": null
  },
  "extracted_evidence": [
    {
      "id": 1,
      "quote": "Flublok is approved for use in persons 18 years of age and older. (1)",
      "relevance_explanation": "This quote explicitly states that Flublok is approved for use in persons 18 years of age and older, directly supporting the claim."
    },
    {
      "id": 2,
      "quote": "Flublok quad rival ent has been administered to and safety data collected from 4328 adults 0 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).",
      "relevance_explanation": "This quote indicates that Flublok Quadrivalent has been administered to adults 18 years and older, supporting its approval for this age group."
    },
    {
      "id": 3,
      "quote": "Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.",
      "relevance_explanation": "This quote shows clinical study enrollment of adults 18 through 49 years receiving Flublok Quadrivalent, supporting its use and approval in adults 18 years and older."
    }
  ],
  "model_used": "gpt-4.1-mini"
}